Tobira Therapeutics, Inc. (TBRA): Capital Management L Pentwater , 10% owner of Tobira Therapeutics, Inc. purchased 1,624,200 shares on Sep 20, 2016. The Insider buying transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were purchased at $39.17 per share for a total value of $63410064 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 13, 2016, A/s Novo (10% owner) sold 59,067 shares at $12.06 per share price.
Tobira Therapeutics Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Tobira Therapeutics Inc which led to swings in the share price. The shares opened for trading at $33 and hit $41.39 on the upside , eventually ending the session at $38.91, with a gain of 720.89% or 34.17 points. The heightened volatility saw the trading volume jump to 1,27,64,728 shares. The 52-week high of the share price is $41.39 and the company has a market cap of $732 M . The 52-week low of the share price is at $3.76.
Company has been under the radar of several Street Analysts.Tobira Therapeutics Inc is Downgraded by Cantor Fitzgerald to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Sep 21, 2016.Tobira Therapeutics Inc is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $27. The Rating was issued on Jul 6, 2016.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.